Craig Roberts

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9815306/publications.pdf

Version: 2024-02-01

414414 394421 1,100 32 19 32 citations h-index g-index papers 32 32 32 1701 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A systematic review and meta-analysis of misuse of antibiotic therapies in the community. International Journal of Antimicrobial Agents, 2005, 26, 106-113.	2.5	209
2	Rates and characteristics of intensive care unit admissions and intubations among asthma-related hospitalizations. Annals of Allergy, Asthma and Immunology, 2004, 93, 29-35.	1.0	106
3	Barriers to adherence and hypertension control in a racially diverse representative sample of elderly primary care patients. Pharmacoepidemiology and Drug Safety, 2009, 18, 672-681.	1.9	85
4	A Systematic Literature Review of Psychosocial and Behavioral Factors Associated with Initial Medication Adherence: A Report of the ISPOR Medication Adherence & Decial Interest Group. Value in Health, 2013, 16, 891-900.	0.3	78
5	Impact of reduced human papillomavirus vaccination coverage rates due to COVID-19 in the United States: A model based analysis. Vaccine, 2021, 39, 2731-2735.	3.8	69
6	Treatment Patterns in the Months Prior to and After Asthma-Related Emergency Department Visit. Chest, 2004, 126, 75-80.	0.8	48
7	Clinical and Economic Burden of Community-Acquired Pneumonia among Adults in the Czech Republic, Hungary, Poland and Slovakia. PLoS ONE, 2013, 8, e71375.	2.5	48
8	Initial Medication Adherence—Review and Recommendations for Good Practices in Outcomes Research: An ISPOR Medication Adherence and Persistence Special Interest Group Report. Value in Health, 2015, 18, 690-699.	0.3	46
9	The cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugs*. International Journal of Clinical Practice, 2010, 64, 169-181.	1.7	44
10	The Impact of Concordant and Discordant Conditions on the Quality of Care for Hyperlipidemia. Journal of General Internal Medicine, 2008, 23, 1208-1213.	2.6	39
11	Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees. BMC Cardiovascular Disorders, 2010, 10, 29.	1.7	38
12	Assessing the burden of pneumonia using administrative data from Malaysia, Indonesia, and the Philippines. International Journal of Infectious Diseases, 2016, 49, 87-93.	3.3	34
13	The Modeled Lifetime Cost-Effectiveness of Published Adherence-Improving Interventions for Antihypertensive and Lipid-Lowering Medications. Value in Health, 2010, 13, 685-694.	0.3	31
14	Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong. Human Vaccines and Immunotherapeutics, 2016, 12, 403-416.	3.3	31
15	Morbidity and mortality of pneumonia in adults in six Latin American countries. International Journal of Infectious Diseases, 2013, 17, e673-e677.	3.3	30
16	Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. Transplant Infectious Disease, 2007, 9, 182-188.	1.7	25
17	Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States. Human Vaccines and Immunotherapeutics, 2021, 17, 1943-1951.	3.3	24
18	The health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) during an annual influenza epidemic and influenza pandemic in China. BMC Infectious Diseases, 2015, 15, 284.	2.9	22

#	Article	IF	CITATIONS
19	Incremental effectiveness of amlodipine besylate in the treatment of hypertension with single and multiple medication regimens. American Journal of Hypertension, 2004, 17, 676-683.	2.0	19
20	Economic Evaluation of Atorvastatin for Prevention of Recurrent Stroke Based on the SPARCL Trial. Value in Health, 2009, 12, 880-887.	0.3	14
21	Adherence to Aldosterone-Blocking Agents in Patients with Heart Failure. American Journal of Therapeutics, 2010, 17, 446-454.	0.9	11
22	Economic Evaluation of Voriconazole for the Treatment of Candidemia in Canadian Adults. Canadian Journal of Infectious Diseases and Medical Microbiology, 2008, 19, 219-226.	1.9	10
23	Inhaled corticosteroids vs leukotriene receptor antagonists: health care costs across varying asthma severities. Annals of Allergy, Asthma and Immunology, 2006, 97, 236-243.	1.0	8
24	Response to "Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries― Vaccine, 2011, 29, 7589-7590.	3.8	7
25	Planning for monitoring the introduction and effectiveness of new vaccines using real-word data and geospatial visualization: An example using rotavirus vaccines with potential application to SARS-CoV-2. Vaccine: X, 2021, 7, 100084.	2.1	5
26	Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines. Vaccine, 2021, 39, 6727-6734.	3.8	5
27	Comorbid risk, respondent characteristics and likelihood of pneumococcal vaccination versus no vaccination among older adults in Brazil. Expert Review of Vaccines, 2014, 13, 175-184.	4.4	4
28	Predicted Coronary Heart Disease Risk Reduction and Dual Blood Pressure/Cholesterol Goal Attainment in Patients With Hypertension Treated in Realâ€World Clinical Practice. Journal of Clinical Hypertension, 2010, 12, 396-406.	2.0	3
29	Cost-Effectiveness of Atorvastatin in the Primary Prevention of Major Cardiovascular Events in Patients with Type 2 Diabetes in Canada. Canadian Journal of Diabetes, 2009, 33, 363-374.	0.8	2
30	Reply to: Economic evaluation of second generation pneumococcal conjugate vaccines in Norway. Vaccine, 2013, 31, 439-441.	3.8	2
31	Pneumococcal vaccine targeting strategy for older adults: Customized risk profiling. Vaccine, 2014, 32, 990-995.	3.8	2
32	A multiâ€centre comparison of nursing staff time required for the preparation and administration of liposomal amphotericin B and amphotericin B deoxycholate vs. voriconazole. Journal of Clinical Nursing, 2009, 18, 1168-1179.	3.0	1